Health Global News & Press Release Distribution

Health

All
APAC

SURGLASSES Announces Successful First Clinical Implementation of Caduceus S AR Surgical Navigation System in Thailand

ONTARIO, Calif., July 31, 2024 /PRNewswire/ -- Leading augmented reality (AR) medical technology company SURGLASSES today announced that, in collaboration with exclusive distributor Goodlifeintertrade.co. Ltd., it has successfully registered and clinically implemented its AR-based Caduceus S surg...

2024-07-31 21:00 2183

SURGLASSES Announces Successful First Clinical Implementation of Caduceus S AR Surgical Navigation System in Thailand

DermRays Leads the Revolution in Home Hair Removal Devices, Set to Replace Cheap IPL

PLEASANTON, Calif., July 31, 2024 /PRNewswire/ -- DermRays, a leading innovator in skincare technology, is proud to announce its latest breakthrough, spearheading a revolution in home hair removal devices with the introduction of advanced laser technology designed to replace cheap IPL alternative...

2024-07-31 17:10 1291

JelloX Biotech collaborates with Mayo Clinic to develop AI enhanced 3D pathology imaging technology

HSINCHU, July 31, 2024 /PRNewswire/ -- JelloX Biotech Inc. ('JelloX') is pleased to announce that it has entered into a collaboration through a know-how agreement with Mayo Clinic to further develop and validate their 3D digital imaging and AI analysis technology. JelloX previously participated i...

2024-07-31 17:00 1377

Fapon Delivers Customized IVD Solutions for the US Market at ADLM 2024

CHICAGO, July 31, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, is showcasing its innovative IVD total solutions at ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), fromJuly 28 to August 1 in Chicago. Committed to supporting local partners, we del...

2024-07-31 14:42 1232

Fapon Delivers Customized IVD Solutions for the US Market at ADLM 2024

FDA Grants Orphan Drug Designation (ODD) Status to Zymedi's ZMA001 for Pulmonary Arterial Hypertension

INCHEON, South Korea, July 30, 2024 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that its first-in-class antibody treatment ZMA001, currently in development for pulmonary arterial hypertension (PAH), has been designated as an Orphan Drug by the U.S. Food and Drug Administration (FDA). Pul...

2024-07-31 08:00 1643

Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics

SUZHOU, China, July 30, 2024 /PRNewswire/ -- On July 29, 2024, Porton Advanced Solutions ("Porton Advanced") announced that it had reached a strategic cooperation with Guangzhou Geneseed Biotech Co., Ltd ("Geneseed Biotech"). Both sides will combine their respective strengths in the field of gene...

2024-07-30 22:00 2386

Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics

Baird Medical Announces Engagement and Education Program for the Development of Thyroid Microwave Ablation Technology

FRISCO, Texas, July 30, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical"), a leading developer and provider of microwave ablation ("MWA") medical devices inChina and the United States, today announced a cross-market engagement and education program designed at fostering both kno...

2024-07-30 17:00 1684

Synthetica Pioneering Closes a Series A Funding Round to Support Development of Oncolytic Bacterial Therapy for Solid Tumors

SHENZHEN, China, July 30, 2024 /PRNewswire/ -- Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup specializing in synthetic biology for engineering novel living bacterial therapeutics, has recently closed a Series A funding round, led by Boehringer Ingelheim Venture Fund and...

2024-07-30 14:00 1595

Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis

SEONGNAM, South Korea, July 29, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based inSouth Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-...

2024-07-30 06:00 1531

Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin

SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOsChang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN12088)', a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis (IPF), has taken a significant ste...

2024-07-29 20:00 1782

Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ

* Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year * Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year * Net Profit Attributable to the Owners of the Com...

2024-07-29 19:05 4302

Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA

HONG KONG, July 29, 2024 /PRNewswire/ -- Akeso (9926.HK) is delighted to announce that the supplemental biologics license application (sBLA) for its independently developed, world's first-in-class PD-1/VEGF bispecific antibody drug, 依达方® (generic name: ivonescimab Injection), as a monotherapy for...

2024-07-29 17:26 1738

NUS researchers develop a novel technique to fabricate three-dimensional circuits for advanced electronics

CHARM3D paves the way for the efficient printing of free-standing 3D structures that offer high electrical conductivity, self-healing capabilities and recyclability — a boon for electronics in healthcare, communications and security SINGAPORE, July 29, 2024 /PRNewswire/ -- Unlike traditional pri...

2024-07-29 16:17 2013

111 to Announce Second Quarter 2024 Unaudited Financial Results on August 29, 2024 - Conference Call to Follow

SHANGHAI, July 29, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that it will repor...

2024-07-29 13:00 1625

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's ERZOFRI® (pa...

2024-07-28 21:48 2994

ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders

BRISBANE, Calif., July 26, 2024 /PRNewswire/ -- ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a$30 million Series A financing, bringing the total raised so f...

2024-07-26 21:00 3143

HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update

* HanAll reports strong financial performance with second quarter total revenue of31.6 billion KRW, driven by the strong sales from the key products. * HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERATM) ...

2024-07-26 19:00 4520

Sanyou Bio Congratulates Eluminex Biosciences and Foreseen Biotechnology on Major Breakthroughs in Innovative Drug Project

SHANGHAI, July 26, 2024 /PRNewswire/ -- On July 15, Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient inthe United States. This clinical trial, known as LOTUS, is an open-label, multicenter, si...

2024-07-26 18:00 3854

Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , July 25, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immuno...

2024-07-26 10:16 1789

Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024

- Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla - Introduces updated version of Neurophet SCALE PET with centiloid scale feature SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announc...

2024-07-25 21:00 1946

Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024

1 ... 18 19 202122 23 24 ... 280